z-logo
open-access-imgOpen Access
DEVELOPMENT OF EFFERVESCENT TABLETS BASED ON RED GINGER (ZINGIBER OFFICINALE ROSC. VAR. RUBRUM) AND ROSELLA FLOWER (HIBISCUS SABDARIFFA L.)
Author(s) -
Adang Suherman,
Andri Cahyo Kumoro,
Khairul Anam,
Edi Susanto,
Sabrianah Badaruddin
Publication year - 2021
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/13473
Subject(s) - hibiscus sabdariffa , citric acid , granule (geology) , traditional medicine , tartaric acid , food science , chemistry , materials science , medicine , composite material
The COVID-19 virus is still spreading throughout the world, and many efforts are being made to combat the outbreak and develop vaccines. Several traditional plants such as ginger and rosella can increase endurance and ward off various diseases. In this research, effervescent tablets made from ginger and rosella have been developed. Five formulations of effervescent tablets with different concentrations of acid and base mixtures have been made to test their physical properties, both granules, and effervescent tablets. The granule physical properties test results showed that the variation of the mixture of acids and bases had no significant effect on the physical properties of the granules. The physical quality of the granule is following the applicable requirements. The same thing was also found in the weight uniformity test. In contrast, in the brittleness and hardness test, tablet formulation 5 (an acid mixture consisting only of tartaric acid) showed the best results. From the dissolution time test, it was found that the use of a mixture of citric acid and tartrate was able to accelerate the dissolving time compared to the use of one type of acid. From the test results, it can be concluded that formulation five tablets show the best quality of tablets. Further studies need to be done regarding the application of ginger and roselle effervescent tablets to increase the bodys immunity from COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here